SCHEMBL6718311

SCHEMBL6718311

O=C1CCc2c(OCC(=O)c3c4n(c5ccccc35)CCNCC4)cccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 7/20 0.53
HTR2C P28335 7/20 0.53
ABCB1 P08183 2/20 0.42
ALDH1A1 P00352 6/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
LMNA P02545 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
PARP1 P09874 2/20 0.35
TRPM2 O94759 1/20 0.35
HTT P42858 1/20 0.34
ROCK2 O75116 1/20 0.34
TNKS O95271 1/20 0.34
ROCK1 Q13464 1/20 0.34
PARP14 Q460N5 1/20 0.34
PARP10 Q53GL7 1/20 0.34
PARP2 Q9UGN5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6714494 0.95 HTR2A (0.51) HTR2AHTR2CABCB1ALDH1A1MEN1
SCHEMBL6715574 0.86 HTR2A (0.53) HTR2AHTR2CABCB1ALDH1A1SMN1; SMN2
SCHEMBL6714387 0.85 HTR2A (0.57) HTR2AHTR2CALDH1A1MEN1KMT2A
SCHEMBL6711544 0.84 HTR2A (0.58) HTR2AHTR2CALDH1A1LMNAKDM4E
SCHEMBL6714228 0.84 HTR2C (0.53) HTR2AHTR2CALDH1A1MEN1KMT2A
SCHEMBL6713960 0.82 HTR2C (0.58) HTR2AHTR2CALDH1A1KDM4EHPGD
SCHEMBL6714333 0.82 HTR2C (0.58) HTR2AHTR2CALDH1A1MEN1KMT2A
SCHEMBL6711312 0.82 HTR2A (0.58) HTR2AHTR2CALDH1A1MEN1KMT2A
SCHEMBL6716128 0.82 HTR2C (0.61) HTR2AHTR2CALDH1A1MEN1KMT2A
SCHEMBL6718513 0.82 HTR2A (0.55) HTR2AHTR2CALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US claimed
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
EP-1328525-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-A]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-23 EP disclosed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US disclosed
WO-2001072752-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E HTR2A 18/4885HTR2C 7/4885ABCB1 945/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 HTR2A 1403/4885HTR2C 553/4885ABCB1 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.